Boosting Antitumor Immunity with an Expanded Neoepitope Landscape

Remco Nagel, Abhijeet Pataskar, Julien Champagne, Reuven Agami*

*Corresponding author for this work

Research output: Contribution to journalReview articleAcademicpeer-review

6 Citations (Scopus)
16 Downloads (Pure)


Immune-checkpoint blockade therapy has been successfully applied to many cancers, particularly tumors that harbor a high mutational burden and consequently express a high abundance of neoantigens. However, novel approaches are needed to improve the efficacy of immunotherapy for treating tumors that lack a high load of classic genetically derived neoantigens. Recent discoveries of broad classes of nongenetically encoded and inducible neoepitopes open up new avenues for therapeutic development to enhance sensitivity to immunotherapies. In this review, we discuss recent work on neoantigen discovery, with an emphasis on novel classes of noncanonical neoepitopes.

Original languageEnglish
Pages (from-to)3637-3649
Number of pages13
JournalCancer Research
Issue number20
Publication statusPublished - 17 Oct 2022

Bibliographical note

Funding Information:
Funding for the present work was provided by the Dutch Cancer Society (KWF project 13647), the European Research Council (ERC-2018-ADG-GA 832844), and the AVL Foundation.

Publisher Copyright:
©2022 The Authors.


Dive into the research topics of 'Boosting Antitumor Immunity with an Expanded Neoepitope Landscape'. Together they form a unique fingerprint.

Cite this